Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Ana M., Ginsberg, Michelle S., Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219862/
https://www.ncbi.nlm.nih.gov/pubmed/20697842
http://dx.doi.org/10.1007/s12032-010-9640-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219862/
https://www.ncbi.nlm.nih.gov/pubmed/20697842
http://dx.doi.org/10.1007/s12032-010-9640-y

Ejemplares similares